Important : Read Carefully!

Loxtra™

ofloxacin, prednisolone acetate, tetrahydrozoline HCl

Sterile Ophthalmic Suspension

COMPOSITION:

Each ml of Loxtra™ contains: ofloxacin 3.0 mg, prednisolone acetate 2.0 mg, tetrahydrozoline hydrochloride 0.4 mg, benzalkonium chloride 0.05 mg (as preservative), HPMC as a vehicle.

PHARMACOLOGY:

Loxtra™ Sterile Ophthalmic Suspension contains broad-spectrum antibiotic (ofloxacin), used to treat bacterial infections of eye. Prednisolone acetate is a glucocorticoid that inhibits the edema, fibrin deposition, capillary dilatation and phagocytic migration of the acute inflammatory response as well as capillary proliferation, deposition of collagen and scar formation.

Tetrahydrozoline hydrochloride is a sympathomimetic agent with alpha-adrenergic activity and is useful as a conjunctival decongestant. It acts as a local vasoconstrictor reducing the swelling and congestion in the mucous membranes of the conjunctiva.

INDICATIONS:

For corticosteriod responsive inflammatory conditions of the conjunctiva, cornea and anterior segment of the eye where bacterial infection or a risk of bacterial infection exists.

CONTRA-INDICATIONS:

Epithelial herpes simplex keratitis, vaccinia, varicella and many other viral diseases of the cornea and conjunctiva, tuberculosis of the eye, fungal diseases of the ocular structures, hypersensitivity to any ingredient of the medication.

WARNING:

Not for injection into the eye. This ophthalmic product contains benzalkonium chloride as a preservative, which may be deposited in soft contact lenses, therefore this product should not be used while wearing these lenses. These lenses should be removed before application of this product and not re-inserted earlier than 15 minutes after use.

PRECAUTIONS:

1. Avoid Contaminating the applicator tip with material from eye, finger or any other source.
2. As with other anti-infectives, prolonged use may result in over growth of non-susceptible organisms, including fungi. If superficial infection occurs, discontinue the use and institute alternative therapy.
3. Loxtra™ should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity reaction.

ADVERSE REACTIONS:

Local irritation including photophobia, blurred vision, dizziness, numbness, nausea and headache.

DOSAGE AND ADMINISTERATION:

Apply 1 to 2 drops, three to four times daily in the affected eye (s).

STORAGE:

Store at 15° - 25°C. Discard after 30 days opening of the bottle.

PRESENTANTION:

Loxtra™ sterile ophthalmic suspension, in 5ml LDPE bottle.

THIS IS A MEDICAMENT

- Medicament is a product that affects your health, and its consumption contrary to instructions is dangerous for you.
- Follow strictly the doctor's prescription, the method of use and the instructions of the pharmacist who sold the medicament.
- The doctor and the pharmacist are experts in medicine, its benefits and risks.
- Do not by yourself interrupt the period of treatment prescribed.
- Do not repeat the same prescription without consulting your doctor.

Keep medicament out of reach of children

Council of Arab Health Ministers & Union of Arab Pharmacists

Ophthalmics

Loxtra™ is a quality product manufactured by:

جمجوم فارما
Jamjoom Pharma

P.O.Box 6267 Jeddah - 21442- Saudi Arabia

32171043 - Rev. 00/28-01-06